LOUISIANA WHOLESALE DRUG CO., INC. v. SMITHKLINE BEECHAM CORPORATION et al

  1. December 13, 2018

    Direct Buyers Win Cert. In Lamictal Antitrust Suit

    Drug wholesalers who directly purchased GlaxoSmithKline PLC's epilepsy drug Lamictal or a generic version from Teva Pharmaceutical Industries Ltd. won certification Wednesday in their antitrust suit alleging a settlement agreement struck between the two drugmakers delayed generic options from entering the market.

  2. August 22, 2018

    GSK Can Keep Docs Private In Lamictal Antitrust Suit

    A New Jersey federal magistrate judge is standing by her decision that GlaxoSmithKline PLC doesn't have to hand over financial forecasts as part of an antitrust suit accusing the drugmaker of conspiring with Teva Pharmaceutical Industries Ltd. to keep a generic version of the epilepsy treatment Lamictal off the market.

  3. July 03, 2018

    Drug Wholesalers Ask For Cert. Over Lamictal Generic Delay

    A proposed class of drug wholesalers alleging GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. conspired to delay generic competition of the epilepsy treatment Lamictal asked a New Jersey federal judge on Tuesday for certification, reasoning that district courts have allowed similar claims to advance as class actions.

  4. May 22, 2017

    Buyers Want GSK, Teva To Cough Up Info In Lamictal Suit

    GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. have refused to hand over crucial information such as Teva's financial forecasts in a potential class action by buyers alleging that the companies conspired to delay generic competition for epilepsy treatment Lamictal, counsel for purchasers of the drug told a New Jersey federal court on Friday.

  5. January 24, 2014

    Actavis Only Requires Scrutiny Of Cash Deals, Judge Says

    A New Jersey federal judge on Friday again dismissed a proposed antitrust class action against GlaxoSmithKline LLC and Teva Pharmaceutical Industries Ltd. over their agreement postponing the production of a generic epilepsy drug, saying a Supreme Court decision changing the way to evaluate such deals' legality led him to the same conclusion.

  6. December 06, 2012

    K-Dur Doesn't Apply To Authorized Generic Deals, Judge Says

    A New Jersey judge dismissed a putative class action against GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. on Thursday, ruling that the Third Circuit's recent decision subjecting so-called pay-for-delay pharmaceutical patent settlements to tougher antitrust scrutiny only applied to deals including cash payments.

  7. October 24, 2012

    GSK, Teva Can't Put Brakes On Pay-For-Delay Challenge

    GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. on Tuesday failed to pause class action allegations that they conspired to keep a generic drug off the market, after a New Jersey federal judge said the U.S. Supreme Court wasn't likely to pick up a similar case potentially affecting the instant suit.

  8. October 09, 2012

    K-Dur Applies To Authorized Generic Deals, FTC Insists

    The Federal Trade Commission on Friday once again urged a federal court to apply the Third Circuit's recent K-Dur ruling on pay-for-delay deals to a case targeting an authorized generic settlement, this time in a putative class action against GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd.

  9. August 16, 2012

    GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy

    GlaxoSmithKline LLC and Teva Pharmaceuticals USA Inc. urged a New Jersey federal judge on Wednesday to dismiss a putative class action that accuses them of conspiring to keep a generic epilepsy drug off the market, saying the licensing agreement relating to GSK's patent exclusivity is protected by law from antitrust litigation.

  10. February 23, 2012

    GSK, Teva Face Antitrust Class Action Over Lamictal Deal

    A drug distributor lodged a putative antitrust class action against GlaxoSmithKline PLC and Teva Pharmaceutical Industries Ltd. in New Jersey federal court Wednesday, accusing the companies of conspiring to keep a generic epilepsy drug off the market in order to maximize profits.